search
Back to results

ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms (ADEQUATE)

Primary Purpose

Respiratory Tract Infections

Status
Terminated
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
BioFire
Sponsored by
UMC Utrecht
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Respiratory Tract Infections

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults (≥18 years old) presenting to the Emergency Room with an acute illness (present for 14 days or less) with cough, and with at least 1 other lower respiratory tract symptom or clinical sign at physical examination:

    • Sputum production,
    • Breathlessness,
    • Chest discomfort or chest pain,
    • Wheeze,
    • Crackles,
    • Self-reported dystermia or documented fever;
    • Documented hypoxemia (adjusting definition for chronic oxygen therapy users, method of measurement) and no alternative explanation (infection, such as sinusitis; other, such as asthma).

      2. Managing medical team considers:

      1. to treat patient with antibiotics and/or to hospitalize patient

        AND

      2. that the rapid syndromic diagnostic test result can be awaited up to a maximum of 4 hours before the decision to discharge the patient or to initiate antibiotic therapy.

Exclusion Criteria:

  1. Development of ARTI more than 48 hours after hospital admission (hospital acquired);
  2. Patients with cystic fibrosis;
  3. Less than 14 days since the last episode of respiratory tract infection;
  4. Pregnancy (confirmed by pregnancy test) and breastfeeding;
  5. Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases or patients with short life expectancy;
  6. Inability to obtain informed consent from a competent patient.

    Based on standard of care microbiological diagnosis and thoracic imaging (when indicated):

  7. Radiologically confirmed acute lobar pneumonia;
  8. Known or suspected Pneumocystis jirovecii pneumonia or active tuberculosis;
  9. Alternative noninfectious diagnosis that explains clinical symptoms (pulmonary embolism, alveolar hemorrhage, acute heart failure, lung cancer).

Sites / Locations

  • University Hospital Schleswig-Holstein

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention

Standard of Care

Arm Description

Outcomes

Primary Outcome Measures

Days alive out of hospital (superiority endpoint)
Days on Therapy (DOT) with antibiotics (superiority endpoint)
Adverse outcome (non-inferiority safety endpoint)
For initially non-admitted patients: any admission or death For initially hospitalized patients: any readmission, ICU admission >= 24 hours after hospitalization, or death

Secondary Outcome Measures

Direct costs and indirect costs within 30 days after enrolment.
Cost of healthcare within 30 days after enrolment, including hospital and ICU days, utilisation of non-hospital services and cost of anti-infective and concomitant medication Cost of workdays lost within 30 days, including days for childcare
Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.
Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.
Microbiological results obtained as standard of care and with the diagnostic intervention
Proportion of participants with an identified respiratory pathogen in both study groups on randomisation day samples.
Empirical antibiotics based on antimicrobial agent categories
Proportion of participants on non-first-line anti-infective regimens (as defined by local guidelines)
Antibiotic type switches and de-escalation based on antimicrobial agent categories
Time to de-escalation and time to stop of anti-infective therapy
Detection of antimicrobial resistance (carriage or infection) related to the diagnostic intervention results compared to standard of care and impact on antimicrobial stewardship guidelines and prevention of hospital acquired infections.
Proportion of hospitalised participants with detection of cephalosporin-, carbapenem- or chinolone-resistant Enterobacteriaceae on any standard of care samples >7 days after randomisation
Impact on decisions regarding isolation measures related to test result.
Hours in individual or cohort isolation in hospitalised participants

Full Information

First Posted
September 7, 2020
Last Updated
November 7, 2022
Sponsor
UMC Utrecht
Collaborators
BioMérieux
search

1. Study Identification

Unique Protocol Identification Number
NCT04547556
Brief Title
ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms
Acronym
ADEQUATE
Official Title
ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Terminated
Why Stopped
Difficult recruitment in the context of the pandemic.
Study Start Date
October 25, 2021 (Actual)
Primary Completion Date
May 21, 2022 (Actual)
Study Completion Date
May 21, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
UMC Utrecht
Collaborators
BioMérieux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To assess the impact of rapid diagnostic testing of patients with Acute Respiratory Tract Infection (ARTI) at the emergency department, on (1) hospital admission rates and (2) antimicrobial prescriptions (days of treatment) and (3) the non-inferiority in terms of clinical outcome. Geographical and seasonal variation will be assessed on a real time basis including pathogens of public health interest. The impact will be stratified within age groups and risk factors in order to determine the long-term clinical, public health and economic determinants for the integration of diagnostics in a global and sustainable perspective.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Tract Infections

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
185 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Title
Standard of Care
Arm Type
No Intervention
Intervention Type
Diagnostic Test
Intervention Name(s)
BioFire
Intervention Description
A molecular rapid syndromic testing platform, using the following panels: BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) BioFire FilmArray Pneumonia Panel plus (PP)
Primary Outcome Measure Information:
Title
Days alive out of hospital (superiority endpoint)
Time Frame
Day 1 - Day 14
Title
Days on Therapy (DOT) with antibiotics (superiority endpoint)
Time Frame
Day 1 - Day 14
Title
Adverse outcome (non-inferiority safety endpoint)
Description
For initially non-admitted patients: any admission or death For initially hospitalized patients: any readmission, ICU admission >= 24 hours after hospitalization, or death
Time Frame
Day 1 - Day 30
Secondary Outcome Measure Information:
Title
Direct costs and indirect costs within 30 days after enrolment.
Description
Cost of healthcare within 30 days after enrolment, including hospital and ICU days, utilisation of non-hospital services and cost of anti-infective and concomitant medication Cost of workdays lost within 30 days, including days for childcare
Time Frame
Day 1 - Day 30
Title
Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.
Description
Quality of life as determined by EQ5D-5L (or suitable alternative for age), days away from work if applicable, and healthcare utilisation on day 1, 14, and 30 after enrolment.
Time Frame
Day 1, 14, 30
Title
Microbiological results obtained as standard of care and with the diagnostic intervention
Description
Proportion of participants with an identified respiratory pathogen in both study groups on randomisation day samples.
Time Frame
Day 1
Title
Empirical antibiotics based on antimicrobial agent categories
Description
Proportion of participants on non-first-line anti-infective regimens (as defined by local guidelines)
Time Frame
Day 1 - Day 14
Title
Antibiotic type switches and de-escalation based on antimicrobial agent categories
Description
Time to de-escalation and time to stop of anti-infective therapy
Time Frame
Day 1 - Day 14
Title
Detection of antimicrobial resistance (carriage or infection) related to the diagnostic intervention results compared to standard of care and impact on antimicrobial stewardship guidelines and prevention of hospital acquired infections.
Description
Proportion of hospitalised participants with detection of cephalosporin-, carbapenem- or chinolone-resistant Enterobacteriaceae on any standard of care samples >7 days after randomisation
Time Frame
>7 days after randomisation
Title
Impact on decisions regarding isolation measures related to test result.
Description
Hours in individual or cohort isolation in hospitalised participants
Time Frame
Day 1 - Day 30

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years old) presenting to the Emergency Room with an acute illness (present for 14 days or less) with cough, and with at least 1 other lower respiratory tract symptom or clinical sign at physical examination: Sputum production, Breathlessness, Chest discomfort or chest pain, Wheeze, Crackles, Self-reported dystermia or documented fever; Documented hypoxemia (adjusting definition for chronic oxygen therapy users, method of measurement) and no alternative explanation (infection, such as sinusitis; other, such as asthma). 2. Managing medical team considers: to treat patient with antibiotics and/or to hospitalize patient AND that the rapid syndromic diagnostic test result can be awaited up to a maximum of 4 hours before the decision to discharge the patient or to initiate antibiotic therapy. Exclusion Criteria: Development of ARTI more than 48 hours after hospital admission (hospital acquired); Patients with cystic fibrosis; Less than 14 days since the last episode of respiratory tract infection; Pregnancy (confirmed by pregnancy test) and breastfeeding; Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases or patients with short life expectancy; Inability to obtain informed consent from a competent patient. Based on standard of care microbiological diagnosis and thoracic imaging (when indicated): Radiologically confirmed acute lobar pneumonia; Known or suspected Pneumocystis jirovecii pneumonia or active tuberculosis; Alternative noninfectious diagnosis that explains clinical symptoms (pulmonary embolism, alveolar hemorrhage, acute heart failure, lung cancer).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc Bonten, MD
Organizational Affiliation
UMC Utrecht
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Schleswig-Holstein
City
Lübeck
ZIP/Postal Code
23538
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

ADEQUATE Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms

We'll reach out to this number within 24 hrs